Mr. Palmer was appointed President and CEO of Unigene in June 2010 specifically to turnaround the Company and exploit its considerable unfulfilled potential. Upon Mr. Palmer's arrival, he completed a comprehensive business audit and SWOT analysis resulting in a compelling growth strategy and organizational realignment. In the fourth quarter of 2010 Mr. Palmer recruited a high-performance, custom-built management team specifically for this turnaround assignment, with a particular focus on aggressive corporate/business development and organization-wide partnering and customer orientation. This transition was validated in December of 2010 with the announcement of a multi-million dollar milestone transaction with GSK.
Prior to joining Unigene, Mr. Palmer headed the strategic advisory firm, Creative BioVentures(tm) Corporation and served as CEO of Critical Biologics Corporation, a development-stage critical care company. Previously, Mr. Palmer was Vice President of Business Development at Ohmeda, Inc. During his tenure, Mr. Palmer played a key role in the $1.2 billion sale of Ohmeda to a consortium including Baxter and Becton Dickinson by spinning out Ohmeda's inhaled nitric oxide assets to found INO Therapeutics, Inc. Under his leadership as founding President and CEO, INO Therapeutics commercialized the world's first selective pulmonary vasodilator, INOmax®, establishing a $100 million plus orphan drug revenue stream within the first 24 months of launch with only 13 sales representatives. In 2007, INO Therapeutics was acquired by the critical care company Ikaria for $670 million..
Earlier in his career, Mr. Palmer held positions of increasing responsibility at Reckitt and Colman PLC and Seton Healthcare Group. He received his MBA from the University of Bradford, England and his BSc joint honors in Biochemistry and Applied Molecular Biology from the University of Manchester, England.
Mr. Greg Mayes joined the Company as Vice President Corporate Development and General Counsel on October 4, 2010. Most recently, he was Vice President, General Counsel and Chief Compliance Officer at ImClone Systems Corporation, a wholly owned subsidiary of Eli Lilly and Company. While serving at ImClone in positions of increasing responsibility, Greg supported the clinical development, launch and commercialization of ERBITUX® (cetuximab), was responsible for the development and oversight of the company's first corporate compliance program, and contributed significantly to activities related to Eli Lilly's acquisition of ImClone. Prior to this, Greg was Senior Counsel at AstraZeneca Pharmaceuticals, LP, where he played an integral role in the provision of legal services for the successful development and commercialization of five compounds in the company's cancer portfolio. Earlier, Greg worked in private practice at Morgan Lewis LLP, a large, national law firm and earned his B.S. degree from Syracuse University, cum laude, and his J.D. degree, magna cum laude, from the Temple University School of Law where he was the Articles Editor on the Temple Law Review.
Dr. Mehta has served as our Vice President, Biological Research and Development since March 1, 2005. Dr. Mehta served as our Director of Biological Research and Development from May 2003 through February 2005, as our Director of Molecular and Cell Biology from 1999 through May 2002 and in various other capacities with the Company from 1982 through 1999. Dr. Mehta obtained a Doctorat d'Université degree (equivalent to a Ph.D.) with honors from the Université Louis Pasteur in Strasbourg, France in 1976. Prior to joining Unigene, Dr. Mehta worked at the Cancer Research Institute in Bombay, India and at the University of Nebraska at Lincoln.
Dr. Shields has served as our Vice President, Manufacturing Operations since March 1, 2005. Dr. Shields served as our Director of Plant Operations from 2001 through February 2005, as our Plant Manager from 1995 through 2001, and in various other capacities with the Company from 1989 through 1995. Dr. Shields holds a Ph.D. in biochemistry from the University of Pennsylvania and a B.S. in chemical engineering from the University of Michigan.
Ms. Tavakkol joined Unigene in March, 2010 and was promoted to Vice President of Global Regulatory Affairs in October, 2010. Ms. Tavakkol brings 20 years of pharmaceutical regulatory and research experience to her position. Prior to joining Unigene, she served on the Thrombosis Business Unit senior leadership team for The Medicines Company. Ms. Tavakkol spent 13 years at Novartis Pharmaceuticals Corporation in positions of increasing responsibility in Drug Regulatory Affairs. Early in her career, she worked in biologic drug discovery in both industry and academic settings. She holds a Masters Degree in Molecular Biology from The Ohio State University.
Ms. Thomas brings to Unigene extensive investor relations and corporate communications experience in the biopharmaceutical industry, both in public and private companies. Ms. Thomas joins Unigene from Amicus Therapeutics, where she served as Director, Investor Relations and Corporate Communications. Prior to Amicus, she was the CEO and President of JDT Communications where she provided investor relations and corporate communications counsel and created fully integrated communications plans for companies including Enzon Pharmaceuticals and Regado Biosciences. Previously, Ms. Thomas served as Senior Director, Investor Relations and Corporate Communications at Aeterna Zentaris. As the company's first U.S. employee, Ms. Thomas rapidly established broad awareness in the U.S. with analysts and other stakeholders in the financial community. She also held investor relations positions of increasing responsibility at Savient Pharmaceuticals, Reliant Pharmaceuticals and Pharmacia Corporation.
Mr. Brian Zietsman, our Executive Director of Finance, joined the Company in April 2012. Mr. Zietsman brings more than 20 years of accounting experience to his position of which more than ten years are in the pharmaceutical industry, both in public and private companies. Prior to joining Unigene, Mr. Zietsman was the Corporate Controller at Duff & Phelps (NYSE DUF) from June 2011 to April 2012. Before joining Duff & Phelps, Brian served as a consultant at Enzon Pharmaceuticals, Inc., (NASDAQ – ENZN) from May 2011 through June 2011. Mr. Zietsman was the Vice President and Corporate Controller at Enzon a position that he assumed in October 2007 through April 2011. Prior to that Brian was Enzon’s Corporate Controller from November 2005. At Enzon Mr. Zietsman was responsible for overseeing all the Company’s accounting functions. Prior to Enzon Brian was the Corporate Controller at Reliant Pharmaceuticals, Inc., (June 2002 – October 2005) a privately held company which was acquired by GlaxoSmithKline in 2007. From May 2001 to June 2002 Mr. Zietsman was Reliant’s Director of Financial Reporting. Earlier Mr. Zietsman worked at Deloitte (April 1994 – May 2001) and held various levels of increasing responsibility when he left as a Senior Manager in the audit group. Brian is a graduate from Rhodes University, South Africa where he earned his B. Com (Accounting), BSc (Computer Science) and HDIPACC certifications. Brian is a registered CPA.
Sitemap |
|
Ethics and Business Conduct Policy |
